Novocure Announces 13 Presentations and a Symposium on Tumor Treating Fields at the 70th Annual Meeting of the German Society of Neurosurgery

For the first time at this conference, a session on Tumor Treating
Fields will be held

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced 13 presentations and a symposium
on Tumor Treating Fields at the 70th Annual Meeting of the German
Society of Neurosurgery (DGNC) on May 12 through May 15 in Würzburg,
Germany. The presentations are part of a Tumor Treating Fields session,
which is a first for Novocure at this conference. Of the presentations,
six are oral presentations and seven are posters. A lunch symposium will
feature seven speakers on Tumor Treating Fields-related topics.

“We are pleased that Tumor Treating Fields has become a significant part
of the dialogue at DGNC,” said Thomas Hefti, Vice President of Europe
and Emerging Markets at Novocure. “DGNC provides a forum for the
exchange of important scientific information. We look forward to sharing
our science on Tumor Treating Fields and contributing to the discussion.”

Oral Presentations

(V001) The use of TTFields for newly diagnosed GBM patients in Germany
in routine clinical care (TIGER – TTFields in Germany in routine
clinical care). O. Bähr (Frankfurt am Main, Frankfurt), M. Glas (Essen).
8 to 8:10 a.m. CEST May 13
Studie zur Anwendung von TTFields in der
klinischen Routine, bei Patientinnen und Patienten mit einem
neudiagnostizierten Glioblastom in Deutschland (TIGER Studie).

(V002) Tumour-treating fields (TTF) with different settings in different
glioma cell lines. G. Hatipoglu Majernik (Hannover). 8:10 to 8:20 a.m.
CEST May 13
Tumortherapiefelder (TTF) mit unterschiedlichen
Einstellungen in verschiedenen Gliomzelllinien

(V003) The blood brain barrier (BBB) permeability is altered by tumour
treating fields (TTFields) in vitro and in vivo. E. Salvador (Würzburg).
8:20 to 8:30 a.m. CEST May 13
Die Permeabilität der
Blut-Hirn-Schranke wird durch Tumor Treating Fields (TTFields) in vitro
und in vivo beeinflusst

(V004) The effect of tumour treating fields on cell morphology and
invasion of different cancer cells. A. Kinzel (München). 8:30 to 8:40
a.m. CEST May 13
Die Wirkung von Tumortherapiefeldern auf die
Zellmorphologie und Invasion verschiedener Tumorzellen

(V005) Increased survival benefit for newly diagnosed glioblastoma
patients with higher TTFields doses to the tumour bed. Z. Bomzon (Haifa,
IL). 8:40 to 8:50 a.m. CEST May 13
Höhere TTFields Dosen im
Tumorbett erhöhen den Überlebensvorteil bei Patienten mit einem neu
diagnostizierten Glioblastom

(V006) Open-label phase 1 clinical trial testing personalised and
targeted skull remodelling surgery to maximise TTFields intensity for
recurrent glioblastoma – interim analysis and safety assessment
(OptimalTTF-1). N. Mikic (Aarhus, DK). 8:50 – 9 a.m. CEST May 13
Open-label
Phase 1 Studie zur Untersuchung einer personalisierten und
zielgerichteten Remodellierungsoperation zur Maximierung der TTFields
lntensität beim rezidivierenden Glioblastom – Interim-Analyse und
Sicherheitsbewertung (OptimalTTF-1).

Poster Presentations

(P169) The dielectric properties of intracranial tumours. M. Proescholdt
(Regensburg). 1:35 to 1:40 p.m. CEST May 14
Die bioelektrischen
Eigenschaften von intrakraniellen Tumoren

(P201) Aurora kinase inhibition to enhance tumour treating fields
(TTFields) efficacy in glioblastoma treatment. D. Krex (Dresden). 1:20
to 1:25 p.m. CEST May 14
Die Inhibition von Aurora-Kinasen erhöht
die Effektivität einer Behandlung mit Tumor Treating Fields bei
Glioblastom-Patienten

(P202) Simulation of TTFields distribution within patient-specific
computational head models. Z. Bomzon (Haifa, IL) 1:25 to 1:30 p.m. CEST
May 14
Simulation
der TTFields Verteilung in patientenspezifischen Kopfmodellen

(P203) PriCoTTF – a phase I/II trial of tumour treating fields prior and
concomitant to radiotherapy in newly diagnosed glioblastoma. L.
Lazaridis (Essen). 1:30 to 1:35 p.m. CEST May 14
PriCoTTF
– eine Phase I/II Studie zu Tumortherapiefeldern vorausgehend und
konkomitant zu Strahlentherapie und Temozolomid im neudiagnostizierten
Glioblastom

(P205) Safety and adverse event profile of tumour treating fields in
elderly patients – a post-market surveillance analysis. L. Lazaridis
(Essen). 1:40 to 1:45 p.m. CEST May 14
Sicherheitsprofil
von Tumortherapiefeldern (TTFields) in älteren Patienten – eine
Post-Market Surveillance Analyse

(P206) Safety and adverse event profile of tumour treating fields use in
the EMEA region – a real-world data analysis. L. Lazaridis (Essen) 1:45
to 1:50 p.m. CEST May 14
Sicherheitsprofil
von Tumortherapiefeldern (TTFields) in der EMEA Region – Datenanalyse
aus der klinischen Routine

(P207) Effect of tumour-treating fields plus chemotherapy in patients
with recurrent glioblastoma. P. Spindler (Berlin) 1:50 to 1:55 p.m. CEST
May 14
Der
Effekt von ‘tumor-treating fields’ als Zugabe zu Chemotherapie in
Patienten mit Glioblastom-Rezidiv

Lunch Symposium

12:15 to 1:15 p.m. CEST May 14

• D. Krex: Aurora kinase inhibition in combination with tumour treating
fields (TTFields) (German)
Aurora-Kinase-Inhibierung in Kombination
mit Tumortherapiefeldern (TTFields)

• L. Lazaridis: Clinical experience with the combination of TTFields
with CCNU/TMZ (CeTeG) (German)
Klinische Erfahrungen mit der
Kombination von TTFields und CCNU/TMZ

• C. Kramm: TTFields in pediatric patients
TTFields bei
pädiatrischen Patienten

• M. Stein: Proton boost and Optune therapy in glioblastoma
Protonenboost-
und Optune-Therapie beim Glioblastom

• M. Glas: TTFields and radiation – recent data and clinical developments
TTFields
in Kombination mit Strahlentherapie – aktuelle Daten und klinische
Entwicklungen

• M. Proescholdt: Comptune: Identification of parameters relevant for
compliance in TTFields therapy
Comptune: Identifikation
compliance-relevanter Parameter bei TTFields Behandlung

• A. Kessler: Experience with TTFields and meetings of patients using
TTFields in Wuerzburg (German)
Erfahrungen mit TTFields und
Patiententreffen von TTFields Patienten in Würzburg

About Novocure

Novocure is a global oncology company working to extend survival in some
of the most aggressive forms of cancer by developing and commercializing
its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is
a cancer therapy that uses electric fields tuned to specific frequencies
to disrupt solid tumor cancer cell division. Novocure’s commercialized
product is approved for the treatment of adult patients with
glioblastoma. Novocure has ongoing or completed clinical trials
investigating Tumor Treating Fields in mesothelioma, brain metastases,
non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver
cancer.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New
Hampshire, Malvern, Pennsylvania and New York City. Additionally, the
company has offices in Germany, Switzerland, Japan and Israel. For
additional information about the company, please visit www.novocure.com
or follow us at www.twitter.com/novocure.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this
press release may contain forward-looking statements. Forward-looking
statements provide Novocure’s current expectations or forecasts of
future events. These may include statements regarding anticipated
scientific progress on its research programs, clinical trial progress,
development of potential products, interpretation of clinical results,
prospects for regulatory submission and approval, manufacturing
development and capabilities, market prospects for its products,
coverage, collections from third-party payers and other statements
regarding matters that are not historical facts. You may identify some
of these forward-looking statements by the use of words in the
statements such as “anticipate,” “estimate,” “expect,” “project,”
“intend,” “plan,” “believe” or other words and terms of similar meaning.
Novocure’s performance and financial results could differ materially
from those reflected in these forward-looking statements due to general
financial, economic, regulatory and political conditions as well as more
specific risks and uncertainties facing Novocure such as those set forth
in its Annual Report on Form 10-K filed on February 28, 2019, with the
U.S. Securities and Exchange Commission. Given these risks and
uncertainties, any or all of these forward-looking statements may prove
to be incorrect. Therefore, you should not rely on any such factors or
forward-looking statements. Furthermore, Novocure does not intend to
update publicly any forward-looking statement, except as required by
law. Any forward-looking statements herein speak only as of the date
hereof. The Private Securities Litigation Reform Act of 1995 permits
this discussion.

Contacts

Media and Investors:
Ashley Cordova
[email protected]
212-767-7558